search
Back to results

Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients (IGNITE)

Primary Purpose

Acute Respiratory Distress Syndrome, Cardiac Failure, Extracorporeal Membrane Oxygenation Complication

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ventilator
Sponsored by
University of California, San Diego
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Acute Respiratory Distress Syndrome focused on measuring ECMO, ARDS, Ventilator induced Lung Injury, Heart Failure, Pulmonary Failure, Biomarkers

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  • Patient currently on ECMO (Veno-Venous or Venous-Arterial or Venous-Arterial-Venous)
  • Patient that is a potential ECMO candidate.

Exclusion Criteria

  • History of Lung or Cardiac Transplantation
  • Patient is not committed to full support
  • Treating clinician refusal, or unwillingness to commit to controlled ventilation for at least 4-6 hours (if patient is mechanically ventilated)
  • Inability to get informed consent from the patient or surrogate.

Sites / Locations

  • University of California San Diego Health

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Low Driving Pressure Protocol

Arm Description

The patients ventilator driving pressure will be decreased (as tolerated by the patient) for 2 hours while on extracorporeal membrane oxygenation (ECMO) support.

Outcomes

Primary Outcome Measures

Change in plasma IL-6 level from baseline to low driving pressure ventilation
IL-6 is a marker of systemic inflammation, previously used in studies of ECMO and ARDS.

Secondary Outcome Measures

Change in plasma sRAGE from baseline to low driving pressure ventilation
sRAGE is a marker of systemic inflammation and acute lung injury, previously used in studies of ECMO and ARDS.

Full Information

First Posted
December 9, 2020
Last Updated
January 25, 2023
Sponsor
University of California, San Diego
search

1. Study Identification

Unique Protocol Identification Number
NCT04669444
Brief Title
Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients
Acronym
IGNITE
Official Title
Investigation of Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 14, 2020 (Actual)
Primary Completion Date
March 1, 2022 (Actual)
Study Completion Date
March 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Diego

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients in end-stage cardiac failure and/or respiratory failure may be started on a rescue therapy known as Extracorporeal Membrane Oxygenation (ECMO). One of the major clinical questions is how to manage the ventilator when patients are on ECMO therapy. Ventilator Induced Lung Injury (VILI) can result from aggressive ventilation of the lung during critical illness. VILI and lung injury such as Acute Respiratory Distress Syndrome (ARDS) can further increase the total body inflammation and stress, this is known as biotrauma. Biotrauma is one of the mechanisms that causes multi-organ failure in critically ill patients. One advantage of ECMO is the ability to greatly reduce the use of the ventilator and thus VILI by taking control of the patient's oxygenation and acid-base status. By minimizing VILI during ECMO we can reduce biotrauma and thus multi-organ failure. Since the optimal ventilator settings for ECMO patients are not known, we plan to study the impact of different ventilator settings during ECMO on patient's physiology and biomarkers of inflammation and injury.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Respiratory Distress Syndrome, Cardiac Failure, Extracorporeal Membrane Oxygenation Complication, Respiratory Failure, Renal Failure, Critical Illness, Pulmonary Disease
Keywords
ECMO, ARDS, Ventilator induced Lung Injury, Heart Failure, Pulmonary Failure, Biomarkers

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single group, intervention
Masking
None (Open Label)
Allocation
N/A
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Low Driving Pressure Protocol
Arm Type
Experimental
Arm Description
The patients ventilator driving pressure will be decreased (as tolerated by the patient) for 2 hours while on extracorporeal membrane oxygenation (ECMO) support.
Intervention Type
Device
Intervention Name(s)
Ventilator
Other Intervention Name(s)
Breathing Machine, Invasive mechanical ventilation
Intervention Description
The patient starts at a ventilator driving pressure of 10-15 cm of H2O as per guidelines for patients on ECMO with ARDS. The driving pressure is then decreased as tolerated for two hours to evaluate the effects on pulmonary, cardiac, and inflammatory biomarkers.
Primary Outcome Measure Information:
Title
Change in plasma IL-6 level from baseline to low driving pressure ventilation
Description
IL-6 is a marker of systemic inflammation, previously used in studies of ECMO and ARDS.
Time Frame
2 hours
Secondary Outcome Measure Information:
Title
Change in plasma sRAGE from baseline to low driving pressure ventilation
Description
sRAGE is a marker of systemic inflammation and acute lung injury, previously used in studies of ECMO and ARDS.
Time Frame
2 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Patient currently on ECMO (Veno-Venous or Venous-Arterial or Venous-Arterial-Venous) Patient that is a potential ECMO candidate. Exclusion Criteria History of Lung or Cardiac Transplantation Patient is not committed to full support Treating clinician refusal, or unwillingness to commit to controlled ventilation for at least 4-6 hours (if patient is mechanically ventilated) Inability to get informed consent from the patient or surrogate.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert L Owens, MD
Organizational Affiliation
UCSD
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Diego Health
City
La Jolla
State/Province
California
ZIP/Postal Code
92037-7381
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Reasonable requests for IPD will be considered by the investigators.

Learn more about this trial

Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients

We'll reach out to this number within 24 hrs